chevron_leftBack
As of 13 June 2026, bioAffinity Technologies, Inc. has a market cap of $10.94M USD, ranking #40805 globally and #5285 in the United States.
It ranks #3629 in the Healthcare sector, and #767 in the Medical Devices industry.
Key Stats
Market Cap
$10.94MUSD
Enterprise Value
$5.65MUSD
Revenue (TTM)
$6.16MUSD
EBITDA (TTM)
-$10.07MUSD
Net Income (TTM)
-$14.91MUSD
EBITDA Margin
-163%
Profit Margin
-242%
PS Ratio
1.8
PB Ratio
1.5
Company Profile
Country (HQ)
Sector
Healthcare
Industry
Medical Devices
CEO
Maria Zannes
open_in_new
Employees
57
Founded
2014
IPO
01 Sep 2022
Website
bioaffinitytech.com
open_in_new
warningChart data may be delayed
| 1d | 1w | 1m | 3m | 6m | 1y |
|---|---|---|---|---|---|
| -8.7% | -3.2% | -39% | 93% | -2.4% | -83% |
News
Loading...
BIAF Analyst Forecasts
Loading...
Markets
| Exchange | Ticker | Price |
|---|---|---|
|
BIAF
bioAffinity Technologies Inc
ISIN: US09076W3079
Shares Out.:
Shares Outstanding:
4.535M1
Shares Float:
4.387M2
TV:
TradingView:
SA:
Stock Analysis:
YF:
Yahoo Finance:
GF:
Google Finance:
NQ:
NASDAQ:
BA:
Barron's:
MS:
Morningstar:
|
2.43 USD |
1Market cap is calculated using shares outstanding.
2Float shares are publicly tradable shares, excluding insider-held stock.
About bioAffinity Technologies, Inc.
bioAffinity Technologies, Inc. engages in developing non-invasive diagnostic laboratory tests to detect early-stage lung cancer and other diseases of the lung using flow cytometry and automated analysis in the United States. The company operates through two segments: Diagnostic Research and Development; and Laboratory Services. The company offers CyPath lung which uses flow cytometry technology to detect and analyze cell populations in a person’s sputum, or phlegm, to find characteristics indicative of lung cancer, including cancer and/or cancer-related cells that have shed from a lung tumor. bioAffinity Technologies, Inc. was incorporated in 2014 and is based in San Antonio, Texas.
Similar Companies
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: TMO
|
$173.27B
2M%
|
25.8
|
|
NASDAQ: ISRG
|
$160.73B
1M%
|
56.7
|
|
NYSE: ABT
|
$159.07B
1M%
|
25.6
|
|
NYSE: DHR
|
$126.55B
1M%
|
34.7
|
|
NYSE: SYK
|
$120.69B
1M%
|
38.3
|
|
NYSE: BSX
|
$84.93B
776K%
|
24.5
|
| Name |
Market Cap (USD)
diff.
|
PE | Country |
|---|---|---|---|
NYSE: MDT
|
$101.9B
931K%
|
22.2
|
|
EPA: EL
|
$97.46B
890K%
84.32B EUR
|
36.7
|
|
TSE: 7741
|
$61.41B
561K%
9.83T JPY
|
40.0
|
|
XETRA: SHL
|
$45.47B
415K%
39.34B EUR
|
18.7
|
|
SIX: ALC
|
$36.38B
332K%
28.99B CHF
|
37.9
|
|
|
$30.06B
275K%
203.66B CNY
|
26.0
|
chevron_leftBack